FierceBiotechOriginal article
{"a":[{"_":"RA Capital launches rare disease company Oak Hill Bio onto Nasdaq via SPAC ","$":{"href":"/biotech/ra-capital-launches-rare-disease-company-oak-hill-bio-nasdaq-spac","hreflang":"en"}}]}
IPO/OfferingPositive
AI Analysis
Summary
Rare disease biotech Oak Hill Bio is going public via SPAC merger with RA Capital-sponsored Research Alliance Corporation III (RACC) to fund development of a rare genetic disease candidate.
Outcome Details
SPAC merger announced
Importance:6/10
Sentiment:
0.30
rare diseaseSPACIPONasdaqRA Capital
Related Companies
Read the original article
Published by FierceBiotech on July 27, 2026 1:56 PM